141 related articles for article (PubMed ID: 8728349)
1. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers.
Melia AT; Mulligan TE; Zhi J
J Clin Pharmacol; 1996 Apr; 36(4):352-5. PubMed ID: 8728349
[TBL] [Abstract][Full Text] [Related]
2. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
Weber C; Tam YK; Schmidtke-Schrezenmeier G; Jonkmann JH; van Brummelen P
Eur J Clin Pharmacol; 1996; 51(1):87-90. PubMed ID: 8880057
[TBL] [Abstract][Full Text] [Related]
3. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers.
Melia AT; Mulligan TE; Zhi J
J Clin Pharmacol; 1996 Jul; 36(7):654-8. PubMed ID: 8844449
[TBL] [Abstract][Full Text] [Related]
4. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.
Anschütz M; Wonnemann M; Schug B; Toal C; Donath F; Pontius A; Pauli K; Brendel E; Blume H
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):158-70. PubMed ID: 20137768
[TBL] [Abstract][Full Text] [Related]
5. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers.
Melia AT; Zhi J; Koss-Twardy SG; Min BH; Smith BL; Freundlich NL; Arora S; Passe SM
J Clin Pharmacol; 1995 Aug; 35(8):840-3. PubMed ID: 8522642
[TBL] [Abstract][Full Text] [Related]
6. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers.
Zhi J; Melia AT; Koss-Twardy SG; Arora S; Patel IH
J Clin Pharmacol; 1996 Feb; 36(2):152-9. PubMed ID: 8852391
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
[TBL] [Abstract][Full Text] [Related]
8. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Zhi J; Melia AT; Guerciolini R; Koss-Twardy SG; Passe SM; Rakhit A; Sadowski JA
J Clin Pharmacol; 1996 Jul; 36(7):659-66. PubMed ID: 8844450
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of four controlled-release nifedipine products.
Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Van Dyk M; Van Schalkwyk AM
Biopharm Drug Dispos; 1994 Aug; 15(6):493-503. PubMed ID: 7993987
[TBL] [Abstract][Full Text] [Related]
10. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers.
Melia AT; Koss-Twardy SG; Zhi J
J Clin Pharmacol; 1996 Jul; 36(7):647-53. PubMed ID: 8844448
[TBL] [Abstract][Full Text] [Related]
11. Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine?
Toal CB
J Cardiovasc Pharmacol; 2004 Jul; 44(1):82-6. PubMed ID: 15175561
[TBL] [Abstract][Full Text] [Related]
12. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.
Wonnemann M; Schug B; Schmücker K; Brendel E; van Zwieten PA; Blume H
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):38-48. PubMed ID: 16425970
[TBL] [Abstract][Full Text] [Related]
13. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
Grundy JS; Foster RT
Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
[TBL] [Abstract][Full Text] [Related]
14. Lack of interaction between orlistat and oral contraceptives.
Hartmann D; Güzelhan C; Zuiderwijk PB; Odink J
Eur J Clin Pharmacol; 1996; 50(5):421-4. PubMed ID: 8839667
[TBL] [Abstract][Full Text] [Related]
15. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.
Chung M; Reitberg DP; Gaffney M; Singleton W
Am J Med; 1987 Dec; 83(6B):10-4. PubMed ID: 3503594
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility of nifedipine absorption from GITS tablets: comparison of single-dose pharmacokinetics using 10, 20, 40 and 60 mg nifedipine.
Tateishi T; Okumura K; Orii Y; Tanaka T
Int J Clin Pharmacol Ther; 2004 Jan; 42(1):58-62. PubMed ID: 14756389
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions of nifedipine and quinidine.
Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
Harris RZ; Inglis AM; Miller AK; Thompson KA; Finnerty D; Patterson S; Jorkasky DK; Freed MI
J Clin Pharmacol; 1999 Nov; 39(11):1189-94. PubMed ID: 10579151
[TBL] [Abstract][Full Text] [Related]
20. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.
Zhi J; Melia AT; Koss-Twardy SG; Min B; Guerciolini R; Freundlich NL; Milla G; Patel IH
J Clin Pharmacol; 1995 May; 35(5):521-5. PubMed ID: 7657854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
